Clinical Trials Sponsored by Biohaven Pharmaceutical Holding Company Ltd.

Total 117 results

Pfizer
Biohaven Pharmaceutical Holding Company Ltd.

Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Migraine

United States, France, Spain, Poland, Canada, Italy
Pfizer
Biohaven Pharmaceutical Holding Company Ltd.

Active, not recruiting

Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

Migraine

Spain, United States, France, Canada, Germany, United Kingdom, Poland, Austria, Sweden, Italy
Pfizer
Biohaven Pharmaceutical Holding Company Ltd.

Active, not recruiting

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

United States
Pfizer
Biohaven Pharmaceutical Holding Company Ltd.

Terminated

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders

Temporomandibular Disorders (TMD)

United States
Biohaven Therapeutics Ltd.

Recruiting

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (RISE 3)

Focal Epilepsy

United States
Biohaven Therapeutics Ltd.

Recruiting

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (RISE 2)

Focal Epilepsy

United States
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Clinical Study of T3011 in Subjects With Advanced Melanoma

Advanced Melanoma

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Breast Cancer Brain Metastases

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

Mild to Moderate Ulcerative Colitis

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Acute Ischemic Stroke

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Diabetic Kidney Disease

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

HER2-positive Advanced Solid Tumors

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Sarcoma, Ewing

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

A Food Effect Study of SPH5030 Tablets.

Advanced Solid Tumor

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B002 in Patients With HER2-positive Breast Cancer (B002-101)

Metastatic Breast Cancer | Recurrent Breast Cancer

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Study on Human Mass Balance of SPH3127 Tablets

Primary Mild and Moderate Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers

Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects

Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (T8)

Rheumatoid Arthritis

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

NMO Spectrum Disorder

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.

Advanced Solid Tumor

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer (B003-101)

HER2-positive Breast Cancer

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Drug-drug Interaction Study of SPH3127

Drug Drug Interaction

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Locally Advanced or Metastatic Breast Cancer

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Essential Hypertension

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors

Solid Tumor

China
Shanghai Pharmaceuticals Holding Co., Ltd

Active, not recruiting

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients

Chronic Abnormal Immune Activation in HIV/AIDS

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

CD20 Positive B Cell Non-Hodgkin's Lymphoma

China
Shanghai Pharmaceuticals Holding Co., Ltd

Withdrawn

Phase I Study of SPH1188-11 in NSCLC (SPH1188-11)

NSCLC Stage IV | NSCLC Stage IIIB

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis

Ankylosing Spondylitis

China
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin

Diabetes Mellitus, Type 2

China
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

Janagliflozin Treat T2DM Monotherapy

Diabetes Type 2

China
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

A Multiple Ascending High Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects

Healthy Volunteers

China
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

Pharmacokinetic Interactions of Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth

Healthy Male Volunteers
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

Advanced Breast Cancer | Metastasis Solid Tumors

China
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.

Duodenal Ulcer，DU

China
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

Evaluate the Effects of Food on the Pharmacokinetics of Fadanafil in Healthy Subjects

Healthy

China
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

Food Effect Study of Anaprazole in Healthy Chinese Subjects

Healthy Male Volunteers
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

Evaluate Safety, Tolerability and Pharmacokinetics of Fadanafil （XZP-5849）in Chinese Healthy Adult Male Subjects

Healthy Subject

China
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem in Clinical Healthy Subjects

Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem in Clinical Healthy Subjects

China
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem inClinical Healthy Subjects

Healthy Subject
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo

Vertigo

China
Sihuan Pharmaceutical Holdings Group Ltd.

Terminated

XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Complicated Urinary Tract Infection Including Acute Pyelonephritis

China
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

Open-label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C]-20 mg/100 μCi Anaprazole Sodium Enteric-coated Capsule in Healthy Adult Male Subjects

Healthy Male Volunteers

Clinical Trials Sponsored by Biohaven Pharmaceutical Holding Company Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations